Professional
Added to YB: 2025-07-24
Pitch date: 2025-07-22
ITOS [neutral]
iTeos Therapeutics, Inc.
+0.2%
current return
Author Info
Special Situation Investments focuses on event-driven trades and low risk arbitrage opportunities with short term catalysts. Sign up for the newsletter.
Company Info
iTeos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer.
Market Cap
$447.4M
Pitch Price
$10.13
Price Target
N/A
Dividend
N/A
EV/EBITDA
0.31
P/E
-2.16
EV/Sales
N/A
Sector
Biotechnology
Category
special_situation
iTeos Investors Eye Optionality in $10.05 Buyout and CVR Structure
ITOS: Being acquired at $10.047/share cash + CVR (excess cash above $475M & 80% of RemainCo pipeline). Price matches liquidation value est. Little chance of excess cash distribution given run rate & tax liability. Deal closing expected Q3. Was good optionality play below $10.
Read full article (1 min)